INTRODUCTION The Medical Advisory Panel for the Veterans Health Administration Pharmacy Benefits Management Strategic Healthcare Group (PBM SHG) coordinates the development of guidelines for the pharmacological management of common disease states treated within the Veterans Affairs (VA) system. These documents are based on nationally recognized treatment guidelines and current literature with the purpose of assisting [...]
Continue reading " Uncomplicated Gastroesophageal Reflux Disease "
Speaker: Benjamin Brenner, MD, Associate Professor of Hematology, The Bruce Rappaport Faculty of Medicine, Tech-nicon-Israel Institute of Technology, Haifa, Israel. Enoxaparin (Lovenox®, Aventis), a well-known, low-molecular-weight heparin, has been shown to be safe and comparatively effective in preventing miscarriages in thrombophilic women with a history of recurrent pregnancy loss.
Speaker: John M. Brooks, PharmD, Associate Professor of Pharmacy, College of Pharmacy, The University of Iowa, Iowa City, Iowa. Neutropenia is a common and costly complication of combination chemotherapy in patients with newly diagnosed non-Hodgkin’s lymphoma (NHL). It occurs most often during the first two cycles of treatment and has a significant effect on inpatient [...]
Speaker: Jeffrey E. Lancet, MD, Assistant Professor of Medicine, James P. Wilmot Cancer Center, Rochester School of Medicine and Dentistry, and Admitting Physician, Strong Memorial Hospital, Rochester, New York. Interim results from a phase 2 clinical trial indicate that tip-farnab (Zarnestra™, Johnson & Johnson), a novel farnesyl transferase inhibitor, has beneficial activity in previously untreated [...]
Yttrium 90 Ibritumomab Tiuxetan Radioimmuno-therapy in Relapsed or Refractory Non-Hodgkin’s Lymphoma Speaker: Thomas E. Witzig, MD, Associate Professor of Medicine, Cancer Center Research/Immunology Program, Mayo Clinic College of Medicine, and Hematology, Mayo Clinic, Rochester, Minnesota. According to an analysis of long-term responders, yttrium 90 (Y) ibritumomab tiuxetan (Zevalin®, Biogen Idec) radio-immunotherapy produces durable long-term remissions, [...]
The goal of asthma management is to achieve and maintain control of the disease while minimizing the occurrence or severity of adverse drug events (ADEs) from the therapies used. We know from multiple, large, community-based studies that despite the promulgation of an international effort and guidelines to standardize the assessment and management of asthma, most [...]
Direct information about the patterns of use of anti-IgE therapy is not readily available. An indirect method of assessing patterns of use is to analyze the prior authorization strategies of MCOs associated with this particular therapy. The use of biologic injectables, such as omalizumab, is frequently subjected to prior authorization procedures that ensure medical appropriateness. [...]
